Global disease experts say little is known about China's experience with long-term COVID effects thought to have afflicted millions with debilitating fatigue, brain fog and other symptoms
Novavax applies to WHO for emergency listing of COVID-19 vaccine
Novavax Inc and its partner Serum Institute of India have applied to the World Health Organisation for an emergency use listing of Novavax's COVID-19 vaccine, the company said on Thursday.
Published : 23 Sept 2021, 04:08 PM
Updated : 23 Sept 2021, 04:08 PM
The WHO's emergency use listing is a signal to national regulatory authorities on a product's safety and efficacy.
It is also a prerequisite for export to several countries participating in the COVAX vaccine sharing facility.
Novavax has said it would focus on low- and middle-income countries for initial supplies of the vaccine, as the United States and other Western nations have already vaccinated a large part of their populations with other vaccines.
Novavax had previously said it would apply for the listing in August, marking a slight delay in the filing.
Novavax and Serum Institute, the world's largest vaccine producer, have committed to together provide more than 1.1 billion doses to the COVAX facility, which aims to provide equitable access to COVID-19 vaccines to low- and middle-income countries.
The Novavax shot is a protein-based vaccine, and was shown to be more than 90 percent effective, including against a variety of concerning variants of the coronavirus in a large, late-stage US-based clinical trial.
RELATED STORIES
The demonstrations helped to end COVID restrictions but failed to achieve lasting political change, six participants based in China and overseas say
The agency seeks details on an increase in respiratory illnesses and reported clusters of pneumonia in children, which its China office called a ‘routine’ check
The inquiry is examining the government's response to the coronavirus pandemic that shut large sections of the economy and killed more than 220,000 people in Britain
